Breaking News

Financial Report: Gilead

July 24, 2014

Sovaldi sales drive triple-digit growth in the quarter

Gilead

2Q Revenues: $6.5 billion (+136%)

2Q Earnings: $3.7 billion (+375%)

YTD Revenues: $11.5 billion (+118%)

YTD Earnings: $5.9 billion (+295%)

Comments: Antiviral product sales increased to $6.0 billion in the quarter driven by sales of Sovaldi, which launched in December 2013. Complera/Eviplera sales were $299.5 million, up 59%, and Stribild sales were $269.5 million, up 171%. Atripla sales declined 7% to $870.7 million and Truvada sales were flat in the quarter. Cardiovascular product sales increased to $266.7 million, up 14% with Letairis sales of $144.7 million, and Ranexa sales of $122.0 million.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks